All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 0.69 [0.28; 1.68]
GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Krolewiecki, 2020 0.49 [0.01; 26.05]
0.56 [0.31 ; 1.02 ] FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Krolewiecki, 2020 5 0% 1,573 moderate not evaluable deathsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44]
Dabbous HM, 2020 0.51 [0.02; 15.41]
FACCT Trial, 2021 0.96 [0.44; 2.08]
GS-US-540-5773 (Goldman), 2020 0.73 [0.37; 1.44]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
Hung et al., 2020 0.47 [0.01; 24.30]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Khamis, 2020 0.83 [0.23; 2.96]
Kirti, 2021 0.12 [0.01; 2.36]
Krolewiecki, 2020 0.49 [0.01; 26.05]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
NCT04542694, 2020 1.00 [0.02; 50.90]
Ren, 2020 1.00 [0.02; 55.80]
Solaymani-Dodaran, 2021 1.22 [0.66; 2.26]
Udwadia, 2020 0.50 [0.02; 15.03]
0.79 [0.59 ; 1.07 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, Dabbous HM, 2020, FACCT Trial, 2021, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ren, 2020, Solaymani-Dodaran, 2021, Udwadia, 2020 18 0% 4,523 moderate critical deaths (time to event analysis only)detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
0.64 [0.28 ; 1.48 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,141 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
ELACOI (Standard of care), 2020 0.86 [0.06; 11.36]
I-TECH (Lim), 2022 1.25 [0.87; 1.80]
Li T, 2020 0.48 [0.01; 27.44]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
0.98 [0.68 ; 1.41 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, I-TECH (Lim), 2022, Li T, 2020, NCT04523831 (Mahmud), 2020 7 37% 1,698 moderate not evaluable clinical improvementdetailed results AVIFAVIR, 2020 0.53 [0.13; 2.19]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
Hung et al., 2020 3.92 [1.66; 9.24]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
NCT04542694, 2020 2.10 [1.04; 4.24]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Udwadia, 2020 1.75 [1.10; 2.79]
1.33 [1.00 ; 1.76 ] AVIFAVIR, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Udwadia, 2020 11 73% 3,073 moderate low clinical improvement (14-day)detailed results AVIFAVIR, 2020 0.53 [0.13; 2.19]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
GS-US-540-5773 (Goldman), 2020 1.53 [1.02; 2.29]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
Ruzhentsova T, 2020 1.28 [1.05; 1.56]
1.24 [1.03 ; 1.48 ] AVIFAVIR, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020 8 25% 2,632 moderate not evaluable clinical improvement (21-day)detailed results Li T, 2020 2.09 [0.04; 119.96]
2.09 [0.04 ; 119.96 ] Li T, 2020 1 0% 18 NA not evaluable clinical improvement (28-day)detailed results GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
Ruzhentsova T, 2020 1.11 [0.96; 1.29]
Udwadia, 2020 1.75 [1.10; 2.79]
1.47 [1.06 ; 2.04 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020, Udwadia, 2020 4 59% 1,102 moderate not evaluable clinical improvement (7-day)detailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35]
GS-US-540-5773 (Goldman), 2020 1.46 [0.95; 2.23]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
Kirti, 2021 0.90 [0.77; 1.06]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
NCT04542694, 2020 2.10 [1.04; 4.24]
Ruzhentsova T, 2020 1.50 [1.02; 2.21]
1.28 [1.01 ; 1.62 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Kirti, 2021, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020 8 69% 2,355 moderate serious clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 0.85 [0.62; 1.16]
GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
Hung et al., 2020 3.92 [1.66; 9.24]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Shinkai, 2021 1.40 [0.91; 2.15]
Solaymani-Dodaran, 2021 0.94 [0.75; 1.17]
Udwadia, 2020 1.75 [1.10; 2.79]
1.22 [1.01 ; 1.49 ] FACCT Trial, 2021, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, NCT04523831 (Mahmud), 2020, Ruzhentsova T, 2020, Shinkai, 2021, Solaymani-Dodaran, 2021, Udwadia, 2020 10 73% 2,828 moderate critical hospital dischargedetailed results FACCT Trial, 2021 0.88 [0.64; 1.21]
Kirti, 2021 1.20 [0.73; 1.98]
Li T, 2020 10.00 [1.03; 97.50]
Udwadia, 2020 1.41 [0.97; 2.03]
1.20 [0.81 ; 1.77 ] FACCT Trial, 2021, Kirti, 2021, Li T, 2020, Udwadia, 2020 4 59% 534 moderate not evaluable mechanical ventilationdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37]
GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
I-TECH (Lim), 2022 0.41 [0.13; 1.30]
Kirti, 2021 0.20 [0.00; 8.69]
Li T, 2020 0.40 [0.04; 3.90]
Solaymani-Dodaran, 2021 1.62 [0.85; 3.08]
Udwadia, 2020 0.06 [0.01; 0.83]
0.78 [0.41 ; 1.49 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Kirti, 2021, Li T, 2020, Solaymani-Dodaran, 2021, Udwadia, 2020 9 51% 2,467 moderate serious mechanical ventilation (time to event analysis only)detailed results Udwadia, 2020 0.06 [0.01; 0.83]
0.06 [0.01 ; 0.83 ] Udwadia, 2020 1 0% 14 NA not evaluable radiologic improvement (14-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
ELACOI (Standard of care), 2020 0.18 [0.01; 3.99]
Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88]
1.17 [0.42 ; 3.26 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Rashad A (AZI vs SoC), 2021 3 16% 252 moderate not evaluable radiologic improvement (7-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
ELACOI (Standard of care), 2020 0.08 [0.00; 1.71]
Ren, 2020 19.00 [0.85; 422.73]
0.53 [0.02 ; 17.19 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Ren, 2020 3 74% 66 moderate not evaluable viral clearance detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Chaccour, 2020 0.92 [0.77; 1.09]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Hung et al., 2020 4.37 [1.86; 10.25]
NCT04542694, 2020 13.03 [2.96; 57.24]
Ren, 2020 28.50 [1.27; 640.66]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Udwadia, 2020 1.37 [0.94; 1.98]
1.88 [1.24 ; 2.86 ] AVIFAVIR, 2020, Chaccour, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Hung et al., 2020, NCT04542694, 2020, Ren, 2020, Ruzhentsova T, 2020, Udwadia, 2020 10 75% 899 moderate critical viral clearance (time to event analysis only)detailed results Hung et al., 2020 4.37 [1.86; 10.25]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Udwadia, 2020 1.37 [0.94; 1.98]
1.69 [1.02 ; 2.78 ] Hung et al., 2020, Ruzhentsova T, 2020, Udwadia, 2020 3 72% 445 moderate not evaluable viral clearance by day 14detailed results AVIFAVIR, 2020 3.08 [0.62; 15.39]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Li T, 2020 1.00 [0.03; 34.67]
Ruzhentsova T, 2020 0.99 [0.93; 1.06]
0.99 [0.93 ; 1.06 ] AVIFAVIR, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Li T, 2020, Ruzhentsova T, 2020 6 0% 366 moderate serious viral clearance by day 7detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Chaccour, 2020 0.92 [0.77; 1.09]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89]
ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
ELACOI (Standard of care), 2020 0.67 [0.10; 4.58]
Kirti, 2021 0.80 [0.43; 1.50]
Ren, 2020 28.50 [1.27; 640.66]
Ruzhentsova T, 2020 1.05 [0.92; 1.20]
1.03 [0.83 ; 1.30 ] AVIFAVIR, 2020, Chaccour, 2020, Dabbous HM, 2020, ELACOI (Lopinavir/ritonavir), 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirti, 2021, Ren, 2020, Ruzhentsova T, 2020 9 43% 603 moderate not evaluable ICU admissiondetailed results FACCT Trial, 2021 1.42 [0.79; 2.55]
I-TECH (Lim), 2022 0.78 [0.27; 2.23]
Khamis, 2020 1.03 [0.35; 3.03]
Kirti, 2021 0.90 [0.30; 2.70]
Solaymani-Dodaran, 2021 1.23 [0.70; 2.18]
1.17 [0.83 ; 1.65 ] FACCT Trial, 2021, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Solaymani-Dodaran, 2021 5 0% 1,318 moderate serious recoverydetailed results GS-US-540-5773 (Goldman), 2020 0.81 [0.64; 1.03]
GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
1.03 [0.83 ; 1.28 ] GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 66% 1,193 moderate not evaluable severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27]
0.30 [0.07 ; 1.27 ] ELACOI (Lopinavir/ritonavir), 2020 1 0% 69 NA not evaluable serious adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10]
GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
Hung et al., 2020 0.23 [0.01; 7.12]
Krolewiecki, 2020 1.00 [0.03; 31.59]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
NCT04542694, 2020 6.15 [0.30; 124.49]
Ren, 2020 1.00 [0.02; 55.80]
Ruzhentsova T, 2020 2.06 [0.09; 46.40]
Shinkai, 2021 2.80 [0.14; 56.95]
Udwadia, 2020 1.03 [0.02; 52.48]
0.75 [0.47 ; 1.20 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ren, 2020, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020 12 0% 2,860 moderate critical acute kidney injury detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18]
1.18 [0.44 ; 3.18 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable adverse eventsdetailed results Chaccour, 2020 1.00 [0.20; 5.07]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78]
GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
Krolewiecki, 2020 1.53 [0.42; 5.58]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
NCT04542694, 2020 1.00 [0.54; 1.85]
Ren, 2020 0.12 [0.01; 2.86]
Ruzhentsova T, 2020 1.90 [0.96; 3.80]
Shinkai, 2021 19.54 [7.77; 49.11]
Udwadia, 2020 6.36 [2.43; 16.65]
1.93 [1.27 ; 2.93 ] Chaccour, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ren, 2020, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020 13 77% 3,089 moderate low arrhythmiadetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69]
2.24 [0.23 ; 21.69 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable elevated liver enzymesdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64]
3.48 [1.40 ; 8.64 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable long QTdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50]
9.79 [1.27 ; 75.50 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 174 NA not evaluable renal impairmentdetailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86]
1.35 [0.47 ; 3.86 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1 0% 331 NA not evaluable serious adverse events (SAE), anydetailed results GS-US-540-5773 (Goldman), 2020 0.50 [0.32; 0.79]
0.50 [0.32 ; 0.79 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable Thromboembolic eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55]
0.89 [0.31 ; 2.55 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-07 07:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 90
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290